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Abstract: Background
Core outcome sets (COS) help to minimise bias in trials and facilitate evidence
synthesis.  Delphi surveys are increasingly being used as part of a wider process to
reach consensus about what outcomes should be included in a COS.  Qualitative
research can be used to inform the development of Delphi surveys. This is an advance
in the field of COS development and one which is potentially valuable; however, little
guidance exists for COS developers on how best to use qualitative methods and what
the challenges are.  This paper aims to provide early guidance on the potential role
and contribution of qualitative research in this area.  We hope the ideas we present will
be challenged, critiqued and built upon by others exploring the role of qualitative
research in COS development.
Methods
This paper draws upon the experiences of using qualitative methods in the pre-Delphi
stage of the development of three different COS.  Using these studies as examples, we
identify some of the ways that qualitative research might contribute to COS
development, the challenges in using such methods and areas where future research
is required.
Results
Qualitative research can help identify what outcomes are important to stakeholders;
facilitate understanding of why some outcomes may be more important than others,
determine the scope of outcomes; identify appropriate language for use in the Delphi
survey and inform comparisons between stakeholder data and other sources, such as
systematic reviews.  Developers need to consider a number of methodological points
when using qualitative research, specifically which stakeholders to involve, how to
sample participants, which data collection methods are most appropriate, how to
consider outcomes with stakeholders and how to analyse these data.  A number of
areas for future research are identified.
Conclusions
Qualitative research has the potential to increase the research community's confidence
in COS, although this will be dependent upon using rigorous and appropriate
methodology.  We have begun to identify some issues for COS developers to consider
in using qualitative methods to inform the development of Delphi surveys in this article.
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Abstract 
Background  
Core outcome sets (COS) help to minimise bias in trials and facilitate evidence synthesis.  Delphi 
surveys are increasingly being used as part of a wider process to reach consensus about what 
outcomes should be included in a COS.  Qualitative research can be used to inform the development 
of Delphi surveys. This is an advance in the field of COS development and one which is potentially 
valuable; however, little guidance exists for COS developers on how best to use qualitative methods 
and what the challenges are.  This paper aims to provide early guidance on the potential role and 
contribution of qualitative research in this area.  We hope the ideas we present will be challenged, 
critiqued and built upon by others exploring the role of qualitative research in COS development. 
Methods 
This paper draws upon the experiences of using qualitative methods in the pre-Delphi stage of the 
development of three different COS.  Using these studies as examples, we identify some of the ways 
that qualitative research might contribute to COS development, the challenges in using such 
methods and areas where future research is required.  
Results 
Qualitative research can help identify what outcomes are important to stakeholders; facilitate 
understanding of why some outcomes may be more important than others, determine the scope of 
outcomes; identify appropriate language for use in the Delphi survey and inform comparisons 
between stakeholder data and other sources, such as systematic reviews.  Developers need to 
consider a number of methodological points when using qualitative research, specifically which 
stakeholders to involve, how to sample participants, which data collection methods are most 
appropriate, how to consider outcomes with stakeholders and how to analyse these data.  A number 
of areas for future research are identified. 
Conclusions 
Qualitative research has the potential to increase the research community’s confidence in COS, 
although this will be dependent upon using rigorous and appropriate methodology.  We have begun 
to identify some issues for COS developers to consider in using qualitative methods to inform the 
development of Delphi surveys in this article. 
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Background 
Randomised controlled trials (RCTs) typically provide robust evidence, which can be used to inform 
clinical practice and health policy [1]. The outcomes measured within a RCT allow the benefits (or 
harms) associated with an intervention to be quantified.  Outcomes measured in RCTs need to be 
useful and relevant to a range of stakeholders including patients, clinicians, policy makers and 
regulatory agencies [2, 3].  Outcomes are often identified, chosen and specified a priori by the trial 
management team (traditionally researchers and clinicians), sometimes with input from patient and 
public contributors [4].   
The use of numerous varying trial outcomes across a research field or clinical area can be 
problematic.  First, this can reduce the ability of systematic reviewers to synthesise results.  The 
most accessed Cochrane reviews of 2009 all reported problems with heterogeneity of outcomes [5], 
while similar problems were found in an analysis of the clinicaltrials.gov database [6].  Second, lack 
of an accepted standard can lead to reporting bias, based on the significance of the findings [7-9].  
Furthermore, outcomes that are selected solely by researchers or clinicians may not hold relevance 
for other stakeholders, such as patients, carers or other decision makers. 
These problems can be addressed through the development of a Core Outcome Set (COS) for use in 
a clinical area or research field.  A COS is a standardised collection of outcome domains that should 
be reported in all controlled trials within a research area [10].  Trialists are not restricted solely to 
these outcomes and can use additional outcomes to those in the core set; therefore, a COS marks 
the basic requirement of which outcomes need to be measured and reported in all studies in a field 
[11].    Furthermore, COS development is typically focussed initially on what to measure with 
subsequent consideration needed of how to measure those core outcomes.  In this paper we use the 
term “outcome” to refer to outcome domains. 
The rate of development of COS has increased over the last 10 years, to the point where close to 20 
new COS were published in 2013 [12]. Core outcome sets have been developed for use in a wide 
variety of clinical specialities [13], including cancer, rheumatology, neurology  and cardiorespiratory 
research; for use with different populations, such as adults and children; and for use specifically in 
pharmaceutical  or surgical research.  The development of COS is attractive to funders such as the 
National Institute for Health Research and others, as it increases the chance that the ‘value of their 
investments will be greater than the sum of the reports’ [14].   
The methods used in COS development exercises are important as they may influence the final COS 
[3].  Development of a COS can comprise several phases, often starting with a systematic review of 
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published literature to identify what outcomes have been measured in previous trials or studies in a 
clinical area. This may generate a long list of candidate outcomes for a COS.  Consensus methods, 
such as simple face-to-face meetings, nominal group techniques and, increasingly, the Delphi survey, 
may then be used to reach agreement about which outcomes are ‘core’ [13, 3].  The Delphi is often 
followed by a consensus meeting of key stakeholders to agree the final COS.  Qualitative research 
can be used in several of these phases, but our main focus in this paper is to outline the use of 
qualitative research to inform Delphi surveys in COS development.    
A Delphi survey is a sequential process through which the opinions of participants are sought, 
usually anonymously [11]. Participants in a Delphi survey do not interact directly; rather after the 
completion of each round of questionnaires, the collated group responses are fed back to 
participants. In this way, equal weight is given to all those who participate and the risk of an 
individual or group of individuals being overly influential or dominant in the process is reduced [15]. 
Of the 227 COS studies published up to the end of 2014, 38 (17%) included the use of Delphi surveys, 
while the rate of use in ongoing studies appears to be higher still.  The majority of COS studies using 
Delphi survey will use a modified rather than a traditional Delphi.  In a “traditional” Delphi the 
outcomes of potential importance would be identified solely in the first round of the Delphi through 
the use of an open text question [16].  In modified Delphis in COS development, a ‘long list’ of 
outcomes is identified prior to the Delphi survey, often, as noted above, through a systematic review 
of outcomes measured in previous trials.   
However, a list of outcomes identified through such systematic reviews may largely reflect outcomes 
that researchers have thought important to measure, particularly where trials predate the recent 
emphasis on patient and public involvement in the design.  Patients, carers and health care 
professionals might differ to researchers in what outcomes they see as important. Relying solely on 
systematic reviews of previous trials may lead to outcomes that are important to patients and other 
stakeholders being overlooked.  Trialists need to have confidence that the perspectives of all 
relevant stakeholder groups have been heard and that their views of important outcomes are 
incorporated into the Delphi and, depending on the results of the Delphi, into the final COS.  To 
address this COS developers have recently incorporated qualitative research into the development 
process to help ensure that the outcomes in a COS are important to the whole community of 
stakeholders, including patients [13].  Often this has involved qualitative data collection methods 
such as focus groups and one-to-one interviews with patients, carers and health care professionals 
[17, 18].  However, little methodological guidance or precedent is available about how qualitative 
research can best be used to inform this component of COS development [19, 20].   
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Aim 
This paper has two aims.  First, we discuss the potential roles for which primary qualitative research 
may be used in the pre-Delphi stage of the development of a COS.  Second, we highlight 
considerations for conducting primary qualitative research in the pre-Delphi stage of a COS 
development based on our experiences of using qualitative research in three COS development 
processes (Table 1).  
This paper is not intended to be prescriptive; rather it looks to provide early guidance, which we 
hope will be challenged, critiqued and built upon by others exploring the role of qualitative research 
in COS development.  We conclude by identifying a number of areas where future research may be 
beneficial to COS developers. 
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Methods 
The discussions and advice provided in this paper is based upon the experience of authors in 
developing three COS in different research areas, with differing participants and using different 
qualitative data collection methods.  Box 1 summarises the COS developments which have been 
drawn upon. 
Table 1: description of studies used to inform this paper 
 PARTNERS2 [21] CONSENSUS [22] MOMENT [23] 
Study title Core outcome sets for use in 
effectiveness trials involving 
people with bipolar and 
schizophrenia in a 
community-based setting. 
CONSENSUS - Squamous 
Cell 
CarcinOma of the 
OropharyNx: Late PhaSE 
CliNical 
TrialS; Core OUtcomeS  
MOMENT--Management 
of Otitis Media with 
Effusion in Cleft Palate: 
protocol for a systematic 
review of the literature 
and identification of a 
core outcome set using a 
Delphi survey 
Qualitative data 
collection method 
Focus groups and one-to-
one semi-structured 
interviews, with prompts to 
cover key discussion points.  
Topic guide used as an aide 
memoire and iteratively 
updated 
One-to-one or three-way 
semi-structured 
interviews with patients 
and their carers. The topic 
guide comprised prompts 
to ensure key topics were 
explored and was 
iteratively developed.     
Conversational style  
interviews with parents 
including prompts to 
discuss topics identified 
from relevant literature.  
Developmentally 
appropriate interviews 
with children. 
Participants Bipolar and schizophrenia 
service user and their carers 
and healthcare and research 
professionals working in this 
area. 
UK and US patients 
treated for oropharyngeal 
squamous cell carcinoma 
(a type of head? and neck 
cancer) and their carers.  
Parents of children with 
non-syndromic cleft palate 
(including cleft lip and 
palate) between 0-11 
years of age, who had a 
current or past diagnosis 
of OME, and children 
themselves aged 6-11 
years 
Ethical approval Ethical approval for the 
study has been sought and 
granted from the National 
Research Ethics Service 
(NRES) West Midlands – 
Edgbaston (reference no. 
14/WM/0052). 
Ethical approval for this 
study was sought and 
granted in the UK by the 
Liverpool Central Research 
Ethics Committee 
(reference 12/NW/0708). 
Approval at the University 
of Texas MD Anderson 
Cancer Center (Houston, 
TX, USA) was provided by 
the Institutional Review 
Board (protocol number 
2013-0285). 
Ethical approval for the 
qualitative interviews with 
parents and children was 
sought and granted by the 
National Research Ethics 
Service – NRES North East 
Committee – Greater 
Manchester East 
(reference 11/NW/0586). 
The PARTNERS2 COS development is part of a larger NIHR funded project titled: PARTNERS2: development and pilot trial of 
primary care based collaborative care for people with serious mental illness [24]. The MOMENT COS development was part 
of a larger NIHR funded project titled: The management of Otitis Media with Effusion in children with cleft palate 
(mOMEnt): a feasibility study and economic evaluation [25]. The CONSENSUS study was conducted by Aoife Waters as part 
of a PhD, supported by the Medical Research Council via the North West Hub for Trials Methodology Research 
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Results and Discussion 
 
The role of qualitative research in core outcome set development 
As noted above, qualitative research can be used in the in the pre-Delphi stage of a COS 
development for a number of purposes: 
1. Identification of outcomes that are important to stakeholders   
Qualitative research allows COS developers to explore the views of patients, healthcare 
professionals and other stakeholders in order to inform the development of a ‘long-list’ of 
potential outcomes. The discursive nature of qualitative research enables participants to 
explain important features of conditions and treatments in their own terms rather than 
requiring them to engage with a discourse of “outcomes”, which is likely to be unfamiliar to 
those outside clinical research.  If conducted appropriately and rigorously the qualitative 
research should afford stakeholders the opportunity to explore and identify outcomes of 
importance.  In turn, this should promote COS developers confidence that all potentially 
relevant outcomes have been included in the first round of the Delphi survey.  In doing so, 
stakeholders have the opportunity to set the agenda and potentially identify outcomes that 
researchers may not have anticipated.  For example in mOMEnt, participants emphasised 
psychological as well as social consequences of impaired hearing, including frustration and 
behavioural problems in children.  This contrasted with the limited reporting of these 
outcome domains in the literature; of the 49 papers identified in the mOMEnt systematic 
review, two included outcomes related to psychosocial development and six included 
outcomes related to behaviour [25].     
2. Facilitate understanding of not only which outcomes are important, but crucially why they 
are important  
Qualitative research with patients, carers and other stakeholders can allow a greater 
understanding of why an outcome is of importance.  For example, in PARTNERS2 
employment was found to be an important social outcome for many people recovering from 
serious mental illness, and was identified in both the literature review and primary 
qualitative research.  However, the qualitative research allowed us to understand that 
suitable employment was more important than employment per se and that its importance 
stemmed from the financial security, meaningful role, structure to the day or the 
connectedness which attending a workplace can allow.  By illuminating the context in this 
way,  qualitative research can ensure that meaningful and accurate outcomes are taken 
forward into the Delphi survey and brief yet informative descriptions to accompany outcome 
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names are developed to help to ensure that participants can interpret a Delphi survey.  
Furthermore, findings from qualitative research may help to inform discussion at the later 
consensus meeting (particularly if there are disagreements among stakeholders), facilitating 
agreement on the final set.  
3. Determining the scope of outcomes 
Qualitative research may also allow the scope of outcomes to be defined in a way which 
holds most relevance to stakeholders in the Dephi.  Take the example of quality of life, which 
is an often measured and reported outcome in trials.  There are numerous different 
conceptualisations of quality of life that can be measured, varying from broad definitions, 
such as global quality-of-life, capability or well-being, to narrower definitions, such as 
health-related quality-of-life or disease specific quality-of-life.  Furthermore, within health-
related quality-of-life, there are subdomains of physical functioning and psychological well-
being.  Qualitative research can be used to delimit the scope of the domain and ensure that 
the breadth of domain taken forward to the Delphi is appropriate.   
4. Identification of appropriate language for use in a Delphi survey.   
The language used to describe outcomes in clinical trial publications may differ markedly 
from the language used by patients, carers and other stakeholders.  Qualitative research 
that identifies and describes outcomes using participants’ own narratives can help COS 
developers to label and describe outcomes in ways that make sense to the stakeholders 
participating in the Delphi survey.  This is important to ensure a Delphi survey is accessible.  
For example, based on qualitative findings the research team may choose to describe the 
outcome of isolation as “feeling cut off and distant from friends” or the outcome of 
aggression as “getting wound up, angry or lashing out” 
5. Comparison with other stakeholder data or alternative sources of outcome data. 
Finally, outcomes derived from qualitative data collected from different stakeholder groups, 
such as service users, carers and healthcare professionals can be compared within the study 
to understand areas of discordance.  When used in combination with a systematic review of 
current outcomes this can allow the COS developers to assess whether the “standard” 
outcomes used in trials in that research area are inclusive of the outcomes that stakeholders 
think should be measured.  Or, whether the outcomes currently used in a research area may 
be missing important domains and should be supplemented when taken into round one of 
the Delphi survey.  For example, in PARTNERS2 symptoms was identified as an important 
outcome by service users and carers, health care professionals and through the review of 
literature.  However, a clear area of discordance was found whereby service users 
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emphasised “living with existing symptoms” as important, while the health care professional 
data and the review data focused on “symptoms reduction”.  In this case, both outcomes are 
being taken into the Delphi, with correct terminology and descriptions used to ensure the 
differences in the two domains were evident to Delphi participants.      
Deciding when qualitative research might not be needed? 
As discussed above, qualitative research may allow the views of a broad range of stakeholders to be 
included in the development process of a COS and facilitate a move away from researcher only 
selected outcomes.  However, qualitative research can be resource intensive; both in terms of time 
and costs and the requirement for specialist input from qualitative experts.  COS developers may 
want to consider whether such work is needed in the particular clinical area for which they are 
developing the core set.  Developers may want to consider the following points.  What is the level of 
patient and public involvement (PPI) in the research area?  If there has been a high level of PPI input 
into relevant trials and research studies, it may be reasonable to assume that outcomes in the area 
already reflect the perspectives of these stakeholders, although this may be challenged on the 
grounds that PPI is not research.  Developers might also want to explore whether there are existing 
qualitative datasets that could help to identify outcomes of importance to stakeholders.  If relevant 
studies have been conducted in the area, it may be possible for these data to inform the COS 
development through secondary analysis.  How challenging is the phrasing of outcomes in the Delphi 
thought to be?  For populations or areas where participants are likely to be particularly sensitive to 
the wording of outcomes, such as children or end of life care, the extra investment may be beneficial 
to ensure the wording is acceptable and appropriate.  These are some points which developers may 
want to consider; however, this is not an exhaustive list and other considerations may be important.   
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Challenges in using qualitative research to inform the development of core 
outcome sets 
Which Stakeholders to include? 
It is important to consider which stakeholders to include as participants in qualitative research to 
best inform COS development. Being a participant in a qualitative study demands no prior 
knowledge of concepts such as ‘outcomes’, and no understanding of research processes or the 
rationale for COS (see section below on discussing outcomes). Therefore, qualitative data collection 
methods are appropriate when working with stakeholder groups such as patients, carers and health 
care professionals for whom such topics may be unfamiliar.   
Patients have valuable first-hand experience of living with the illness and receiving treatments and 
knowledge about which outcomes are important to them.  Healthcare and health research 
professionals may have experience of treating a number of patients or observing a number of 
research projects and therefore understand how an illness manifests itself in different individuals or 
the different treatment effects in individuals.  Other stakeholders such as carers, who are typically 
spouses or family members, can provide useful perspectives as “involved witnesses”. 
While our experience indicates that patients, carers and professionals tend to identify some similar 
outcome domains as important, there have also been some differences.  For example, in PARTNERS2 
when talking about physical health outcomes patients identified broad areas such as weight gain and 
reduced physical activity; whereas professionals talked about specific clinical outcomes, such as 
diabetes and blood pressure.  Or, when discussing social outcomes, such as being able to participate 
in a work environment, healthcare professionals identified the ability to work as an important 
outcome; whereas patients and carers identified subtly different outcomes of participation in work 
that is appropriate to their condition (e.g. flexible working) and participation in a role that made 
them feel valued as important outcomes. 
Sampling 
The pre-Delphi stage of the development of a COS needs to identify outcomes that are relevant to all 
stakeholders.  Therefore, it is important that the sampling strategy facilitates access to patients, 
carers, professionals and other participant groups who have experience of the illness for which the 
core outcome set is being designed.  If a key aim of pre-Delphi qualitative research is to ensure no 
outcomes are overlooked, there is a strong case for using a sampling strategy designed to identify a 
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maximum variation sample, as this would be more likely to identify the wide range of outcomes of 
interest.   
Purposive sampling can be used to recruit heterogeneous maximum variation samples, where 
people differ by select characteristics [26].  This allows participants to be selected based upon 
characteristics which might be anticipated to influence the outcomes they perceive as important [27, 
28].  Parents of children of all ages in the mOMEnt study identified hearing as an important 
outcome.  However, their concerns about hearing differed between parents of preschool children (0-
4 year olds) who focused on speech and language; parents of young primary school children (5-7 
year olds) who emphasised effects on social interaction; and parents of older primary school 
children (8-11 year olds) who were concerned about social interaction and educational performance 
[25].  These differences highlight the importance of including variation in a sample, in this case 
diversity of age and development of children.   
Qualitative samples are normally smaller in size than quantitative samples, as quantification of 
incidence is not the focus of this research.  Rather the purpose is to collect rich data that allows  in-
depth exploration and understanding of different research questions [29].  Normally there will come 
a point of diminishing return when new interview or focus group data cease contributing to the 
analysis, and the research team will decide to stop data collection (the point of conceptual 
saturation).  In the PARTNERS2 interviews with healthcare and research professionals this was noted 
after 14 interviews, with a further two interviews conducted to check that data saturation had been 
reached.  A larger sample size may be required if particular diversity is needed in some 
characteristics.  For example, as well as sampling participants from both the US and UK, the 
CONSENSUS study aimed to include a diverse group of patients in terms of sociodemographic, 
disease and treatment characteristics and therefore recruited over 30 patients and their carers.   The 
mOMEnt study included a range of three cleft types (palate only or in combination with either 
unilateral or bilateral cleft lip) and four treatment pathways (ventilation tubes, hearing aids, both, or 
watchful waiting) resulting in a qualitative sample of 37 children. 
Discussing trial outcomes 
Qualitative research in the early phases of COS development will be focused on identifying outcome 
domains that are important to participants.  Our experience suggests that the concept of an 
outcome can be rather obscure and challenging for patients, carers anTabled other stakeholders to 
engage with.  Patients and carers cannot be expected to be in a position to engage meaningfully with 
questions such as “what outcomes do you think we should measure in a trial of treatment for your 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
12 
 
illness?” In the mOMEnt study parents did not respond readily to the notion of “outcome”.  
Therefore parents were prompted to consider what they thought an intervention should achieve 
(Table 2).  Despite this two parents did not distinguish between process (for example ‘good 
aftercare’) and outcomes.  In the PARTNERS2 we also found that some healthcare professionals, 
researchers and commissioners also struggled to discuss outcomes directly.     
To address this, careful consideration needs to be given to how outcomes are going to be elicited 
and discussed when designing qualitative research [30].  Normally this planning would involve 
consultation with relevant patient groups in order to inform the design of the research. Further 
consideration and consultation will be needed when developing the topic guide or interview 
schedule, when planning the prompts to be used and when iteratively developing these over the 
course of semi-structured interviewing to expand and explore participants’ accounts.  Encouraging a 
discussion of how an illness has affected a person’s life, which parts of their life they may perceive to 
have lost and what things they hope to gain through treatment/care was found to be a fruitful way 
of approaching the discussion in all three of the studies used as examples in this paper.  In 
CONSENSUS one-to-one interviews allowed patients to provide a chronological narrative of their 
lives as they underwent treatment and beyond. Over the course of their interviews patients spoke of 
how outcomes that were important early in treatment sometimes differed to those that became 
important at later stages.  Interviews for the mOMEnt study commenced by inviting parents to tell 
the story of their child’s OME (or “glue ear”).  These accounts provided narratives of the context of 
experiences of the condition and interventions and included implicit references to outcomes.  As the 
interview progressed the participants were asked to discuss outcomes more explicitly.  While in 
PARTNERS2 participants were encouraged to think back over how their illness had changed their life 
and discuss their goals in living with their condition.  Later in the interview participants were 
encouraged to think about these changes and goals in terms of research outcomes.  For all studies 
used as examples herein, allocating time to these early discussions in focus groups and interviews 
helped to identify outcomes of relevance and provided the basis for later discussions about which of 
the points discussed they felt were relevant to measure as outcomes in a research setting.   
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Table 2: questions and prompts used by authors to discuss outcomes. 
Discussions with patients 
PARTNERS2 
“I would like you to think about how your mental 
health problems have changed your life and what you 
have lost because of them.” 
“This time rather than thinking about what you have 
lost, I would like you think about what your goals are 
in living with your symptoms.” 
“Since your diagnosis and treatment has life changed 
for you? In what ways has life changed?” 
CONSENSUS 
“What’s a good day like for you?  What’s a day like 
which is not so good” 
“What would you say your priorities are in life at the 
moment?  What would you have said if I’d asked that 
question before your illness and treatment?” 
mOMEnt - Discussion with parents 
What do you think grommets (VTs) or hearing aids 
(HAs) should do for a child with glue ear? 
mOMEnt - Discussions with children 
What was ‘good’ and ‘not so good’ about VTs or 
HAs 
Discussions with healthcare/researcher 
professionals 
PARTNERS2 
“How does Schizophrenia/Bipolar affect a person’s 
life?  What do they lose?” 
“What outcomes are you/should we looking to 
achieve when delivering care or support to people 
with bi-polar disorder/schizophrenia?”    
“What are you looking to improve in the person’s 
life?” 
“Are different outcomes important to patients at 
different stages in their illness?  At different stages in 
their health?  Controlled vs Stable?  Diagnosis vs later 
management?” 
 
 
Focus groups or interviews? 
If the purpose of qualitative research prior to a Delphi survey is to identify a complete list of 
outcomes which may be important to stakeholders, then a data collection method that allows the 
patient’s journey to be understood may be most effective. However, if the purpose is to define the 
scope of the outcomes or the language, then an approach that allows convergences and divergences 
between different stakeholders to be identified may be most appropriate.  However, often the 
objective of pre-Delphi qualitative research is to inform both a complete list and increase 
understanding of outcomes, which may call for a mix of qualitative data collection methods.  Focus 
groups and one-to-one interviews are two ways in which qualitative data can be collected.  These 
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two methods of data collection have important differences which need to be considered when 
identifying outcomes in COS development. 
In a one-to-one interview, data are generated through an interaction between the interviewer and 
the participant.  A semi-structured format helps to ensure that the most important aspects are 
covered, while allowing the participant flexibility to explore concepts important to them.  As 
described above this may involve participants giving an account of their illness and treatment 
experience, which researchers can interpret to identify outcomes which are important to patients.   
In a focus group, data are generated through an interaction between the participants which is 
facilitated by the researcher.  Participants are in a position to listen, discuss, agree, question or 
clarify points that are raised by other participants in the group.  This synergistic discussion aims to 
facilitate participants in exploring outcomes which are important to them or the people they care 
for.  Group discussion can help patients to see how their experiences differ to those of other 
participants in the groups and thereby help to identify outcomes which are important to them, or to 
challenge outcomes which are not important to them.  However, there are drawbacks too.  The 
logistics of completing groups can be challenging. Just as some people will dislike the idea of 
participating in an individual interview and prefer being part of a group, others may perceive a group 
discussion as intimidating and inhibitive. Additionally, a typical focus group involving 8-9 participants 
and lasting 90-120 minutes provides each individual with an average of only 10-15 minutes speaking 
time, which can constrain the range of outcomes discussed.   
Our experience of using focus groups in COS development indicates that while outcomes were 
discussed in depth, fewer outcomes were identified and understanding the patient journey and 
outcomes of importance at different stages was difficult.  To address this challenge in PARTNERS2 
we used a number of methods to collect non-verbal data, where participants were given the 
opportunity to write down outcomes of importance to them on slips of paper or ‘post-it’ notes.  
These data were then either used to inform discussion later in the focus group or collected solely as 
written data.  In some instances this exercise was designed to hide the identity of the note’s author 
to allow sensitive outcomes to be identified and subsequently discussed without embarrassment or 
inhibition.       
Analysis of data 
When analysing the data from a qualitative study to support COS development, a focus must be 
maintained upon the particular purpose of the research.  If, as described above, the main purpose of 
the research is threefold (to identify outcomes, define the scope of outcomes and identify common 
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language) this must be reflected in the analysis.  In many cases analytical approaches that code, label 
and index data will facilitate the process of identifying relevant outcome domains for the Delphi.  
Paying attention to and maintaining the language of the study participants will allow identification of 
common language.  This should be part of an interpretive process whereby analysts consider the 
data as a whole in identifying relevant and understandable outcomes. 
In the CONSENSUS study, for example, the coding, labelling and indexing of data, allowed the 
identification that patients tended to talk at length about the impact of treatment on aspects of 
their quality of life and how in contrast, survival was often mentioned only in passing or indirectly. 
One interpretation might be that survival was less important to these patients than aspects of their 
quality of life. However, considering the data and the interview as a whole the CONSENSUS team’s 
interpretation was that issues of life and death were difficult for patients to talk about.  In the 
context of interviews where patients were describing the months of unpleasant treatment that they 
had endured to improve their chances of surviving the illness, the importance of survival did not 
need to be laboured.    
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Future research 
The use of qualitative research in the development of COS is increasing.  This paper has described 
the potential benefits of qualitative research, indicated some of the challenges faced and provided 
examples of methods which may help to overcome them.  The advice and guidance provided in this 
paper, which is not intended to be prescriptive, is based largely on the authors’ experiences of using 
qualitative research in the context of wider COS development projects.  A better understanding of 
the role and contribution of qualitative research in COS development will depend on future 
methodological research.  The following areas are identified as in particular need of such research. 
Methods of data collection.  More knowledge is needed on the differences in data collected from 
one-to-one interviews versus those collected from focus groups.  As noted above our experience 
suggests that differences may arise; however, the nature and impact of differences on what is learnt 
and the associated resource use is not clear without further exploration. By reflecting on the use of 
qualitative data collection methods in COS development exercises to date, future research can be 
designed to assess whether interview and focus group data yield the same depth of meaning and 
understanding about stakeholder preferred outcomes and the extent and implications of any 
differences.  Of course this cannot be considered in isolation from the points below.  
Discussing outcomes.  The way that outcomes are introduced to research participants and the 
framing of the discussion that follows will likely have a notable impact upon data collected.  
Research into the best ways to discuss outcomes with patients, carers and healthcare professionals – 
and whether to avoid overt discussions of “outcomes” altogether – would help to ensure that 
participants are able to fully contribute to COS development process [30]. 
Analysing data.  It is essential to understand the approaches to qualitative analysis that will be most 
informative for COS development.  The need to go beyond a simple cataloguing of outcomes to form 
a deeper understanding of what participants wanted from treatments was identified in each of the 
COS development examples provided here.   
Sampling.  Understanding the impact of different sampling techniques is essential.  As noted above, 
based on our experience, maximum variation sampling seems to be most likely to identify potentially 
important outcomes.  However confirmation of this and the potential effects of convenience or 
opportunistic sampling is vital. 
Use of existing qualitative research.  There is a large and expanding qualitative research literature on 
a wide range of different conditions and treatments and there are likely to be several such studies in 
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particular disease areas that could potentially contribute to COS development, or even avoid the 
need to collect new qualitative data, which can be resource intensive. Where qualitative datasets 
are available, secondary analysis of these may similarly negate the need for primary data collection, 
although research is needed to examine the extent to which such data, which will likely have been 
collected for very different purposes, can be used to inform COS development.  Future research 
about how to usefully incorporate these data into COS development is of importance. 
Conclusion 
The use of qualitative research in the pre-Delphi stage of COS development is a novel 
methodological advance which brings a number of potential benefits.  These benefits all relate to 
the primary goal of ensuring that all stakeholder perspectives are represented in the final COS, 
whether through identification of outcomes, understanding the importance of outcomes or 
identifying patient and carer language.  Our experience suggests that with these benefits come a 
number of challenges.  This paper suggests a number of potential methodological solutions, which 
we hope will be investigated further by researchers in this field. 
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Dear Sir/Madam, 
Thank you for considering our paper on the use of qualitative research to inform the development of Core 
Outcome Sets.  We are submitting this paper to your special issue on qualitative methods, trials and 
systematic reviews thematic series. 
As our paper describes core outcome sets represents a notable development in trial research methodology.  
The COMET initiative (http://www.comet-initiative.org/) has helped to catalogue the development of core 
outcome sets and work towards the development of rigorous methodology for their development.  Over 200 
core outcome set publications are recorded on the COMET database, with a clear indication that the rate of 
development is increasing.   
The use of qualitative methods is a recent methodological advance in the development of core outcome 
sets.  It represents a clear pathway through which qualitative research can contribute to the selection of 
outcomes which are grounded in the values and preferences of stakeholders.  If, as designed, a core 
outcome set is adopted and used throughout a research area, then the potential impact of the qualitative 
research used to develop that set could be considerable. 
There are a number of benefits for using qualitative research in core outcome set development, as well as a 
number of challenges to their use.  As researchers who led the qualitative component of a core outcome set 
development or/and as leaders of the COMET initiative, this paper draws upon our experience of using 
qualitative research to develop core outcome sets.  We highlight the methodological benefits in using 
qualitative research and describe some of the practical solutions used to address these challenges.  The 
advice is not meant to be prescriptive, rather we hope that future research in this area will build on and 
challenge the points made.    
We are sending this paper to you as trials has recently published a number of “highly accessed” articles in 
the area of core outcome set development methodology (Williamson et al 2013) and in the identification of 
outcomes in core outcome set development (Macefield et al 2014).  We also believe that this paper speaks 
to the key aim of the qualitative methods special issue of showcasing a range of qualitative and mixed 
methods research and demonstrating the ways they can support the methodological growth of clinical trials. 
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